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Summary
In developing B cells, expression of surface immuno-
globulin is an important signal to terminate recom-
binase activator gene (RAG) expression and V(D)J
recombination. However, autoreactive antigen recep-
tors instead promote continued gene rearrangement
and receptor editing. The regulation by B cell receptor
(BCR) signaling of RAG expression and editing is
poorly understood. We report that in editing-compe-
tent cells BCR ligand-induced RAG mRNA expression
is regulated at the level of RAG transcription, rather
than mRNA stability. In immature B cells carrying in-
nocuous receptors, RAG expression appears to be
under rapidly reversible negative regulation. Studies
involving transduction of a superrepressive (sr) IB
protein indicate that NF-B/Rel proteins promote RAG
transcription. Interestingly, NFB1-deficient cells over-
express RAG and undergo an exaggerated receptor
editing response. Our data implicate NFB transcrip-
tion factors in the BCR-mediated regulation of RAG
locus transcription. Rapidly activated NFB pathways
may facilitate prompt antigen receptor-regulated
changes in RAG expression important for editing and
haplotype exclusion.
Introduction
Recombinase activator gene products RAG1 and RAG2
are critical for the assembly of antigen receptor gene
variable (V), diversity (D), and joining (J) elements by
DNA recombination (Fugmann et al., 2000). RAG gene
expression is highly restricted by cell type and matura-
tional stage, with highest levels apparent in developing
lymphocytes (Schlissel, 2003; Jankovic et al., 2004).
RAG1 and RAG2 coding sequences are found on the
chromosome near to one another with convergent tran-
scriptional orientations, and these two genes are al-
most invariably expressed together (Fugmann et al.,
2000). In addition, in T and B lymphocyte development
RAG expression occurs in at least two separate waves,*Correspondence: nemazee@scripps.educorresponding respectively to recombination of the two
receptor chains: T cell receptor α and β or immunoglob-
ulin (Ig) H and L (Grawunder et al., 1995; Wilson et al.,
1994). These features indicate that RAG expression is
under stringent and coordinate control.
B cells almost always express a single immunoglobu-
lin (Ig) heavy (H) and light (L) chain on the cell surface,
in part because in developing B cells carrying surface
Ig feedback signaling mechanisms can prevent recom-
bination (for reviews see Storb, 1987; Karasuyama et
al., 1996; Nemazee, 2000). However, B cell receptors
that are ligated by self antigen fail to suppress V(D)J
recombination and promote receptor editing, which can
silence one receptor chain gene and replace it with an-
other (Gay et al., 1993; Radic et al., 1993; Tiegs et al.,
1993). Receptor editing in B cells is strongly correlated
with elevated RAG1 and RAG2 mRNA levels (Hertz and
Nemazee, 1997; Melamed and Nemazee, 1997; Mel-
amed et al., 1998), but the basis of this regulation is
unknown. Steady-state levels of message could be reg-
ulated by differential synthesis, differential degradation,
or both. In B cell lines, both changes in the rates of
RAG transcriptional initiation and degradation may be
under the control of BCR or other signaling pathways
(Neale et al., 1992; Ma et al., 1992; Verkoczy et al.,
1995). However, there have been no studies to our
knowledge that have examined the relative contribu-
tions of message stability and synthesis in the regula-
tion of RAG genes in primary B cells. Nor is it known if
the increased RAG levels in B cells undergoing receptor
editing is regulated by increased transcription or de-
creased RNA degradation.
Key features of RAG transcriptional control have
been elucidated: transcriptional start sites have been
mapped and promoter regions characterized (Schlissel,
2003; Jankovic et al., 2004). RAGs are regulated both
by promoter sequences and by more distant 5# ele-
ments that are presumptive enhancers, locus control
regions, or antisilencers (Kitagawa et al., 1996; Yu et al.,
1999; Monroe et al., 1999; Yannoutsos et al., 2001; Wei
et al., 2002; Hsu et al., 2003; Yannoutsos et al., 2004).
Interestingly, the elements that regulate tissue-specific
expression in B and T cells are different and these same
elements appear to regulate both RAG1 and RAG2 ex-
pression (Yu et al., 1999; Monroe et al., 1999; Hsu et
al., 2003). Transcription factors or cognate binding sites
implicated in RAG gene expression include NFY, Pax5,
c-Myb, GATA-3, E2A, C/EBP, Runx, SP1, and Ikaros
(Fuller and Storb, 1997; Zarrin et al., 1997; Brown et al.,
1997; Kee and Murre, 1998; Lauring and Schlissel,
1999; Fong et al., 2000; Kishi et al., 2000; Wang et al.,
2000; Kishi et al., 2002; Miranda et al., 2002; Jin et al.,
2002; Wei et al., 2002; Hsu et al., 2003; Yannoutsos et
al., 2004; Quong et al., 2004). Despite this progress,
much remains to be learned about the complex regula-
tion of RAG gene expression.
The goals of the present study were to determine if
the tolerance-induced increase in RAG expression of
immature B cells is controlled at the level of RNA tran-
scription or stability, and to determine how BCR signal-
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520Figure 1. Assessment of RAG1 and RAG2 mRNA Stability and Transcription in Immature sIg+ B Cells Carrying an Unligated or Anti-BCR
Ligated Antigen Receptor
Primary bone marrow cells were cultured for 5 days in IL7-containing medium, and then cells were challenged in the absence of IL7 with
control or anti-BCR antibody.
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521thesis inhibitor cycloheximide (CHX) indicated that SN50, but not a control peptide, suppressed BCR-
(A and B) Assessment of decay of RAG1 and RAG2 mRNA levels upon Actinomycin D treatment.
(A) Northern blot RNA analysis of 3-83 transgenic BM B cells cultured in the presence of control antibody (lanes 1–10) or anti-BCR antibody
(lanes 11–20) for 24 hr post IL7 withdrawal, followed by addition of the transcriptional inhibitor Actinomycin D and incubation for the indi-
cated times.
(B) Graphical representation of the data shown in (A), showing RAG1 and RAG2 mRNA levels relative to 18S RNA signal. Initial levels were
set to 100% and the percent signal remaining was plotted as a function of time.
(C and D) Nuclear run-on analysis of RAG1 and RAG2 transcription at 24 hr post IL7. Data shown indicate the fold increases in BCR-stimulated
compared to control Ig-treated cells.
(E) GFP reporter analysis of RAG2 transcription in 3-83 Ig / HYG RAG2-GFP double transgenic BM cells. Panels on right show flow cytometry
analysis of cells cultured post IL7 withdrawal for 48 hr with control or anti-BCR antibody.ing controls RAG mRNA levels. We find that the regula-
tion RAG mRNA levels is virtually entirely at the level of
transcriptional rate. In addition, we have uncovered an
unexpected role for NFκB/Rel transcription factors in
BCR-regulated transcription of the RAG genes, which
may regulate both feedback suppression and toler-
ance-induced stimulation of RAG expression.
Results
RAG RNA Turnover and Transcription in Editing
and Nonediting Primary B Cells
To assess the relative contributions of changes in RNA
stability and transcriptional initiation to the regulation
of RAG mRNA levels in immature B cells, we employed
a culture system in which primary bone marrow (BM)
cells from 3-83 antibody transgenic mice are stimulated
with interleukin 7 (IL7). After 5 days of culture, >95% of
nonadherent cells are B220+ B lineage cells, which,
upon removal of IL7, are competent to undergo recep-
tor editing upon BCR ligation (Melamed and Nemazee,
1997). As shown in Figure 1A, treatment of cultured
cells with anti-BCR antibody led to a marked increase
in the levels of RAG1 and RAG2 mRNAs (compare lanes
1 and 2 to 11 and 12). Treatment of cells with the tran-
scription inhibitor actinomycin D (ActD) allowed an as-
sessment of RNA decay over time. We consistently
found that the half-life of both RAG1 and RAG2 mes-
sages was w30 min and that BCR ligation increased
mRNA levels of RAG1 and RAG2 without significantly
increasing mRNA half-life (Figure 1B).
BCR ligation increased steady state levels of RAG
mRNA in the absence of significant changes in RAG
mRNA stability, suggesting that transcription rates
must be upregulated, a notion that was tested indepen-
dently by transcriptional run-on assay (Figures 1C and
1D). Hybridization signals to immobilized RAG1 and
RAG2 cDNAs were specifically increased several fold
in the samples from BCR-stimulated cells, whereas hy-
bridization to control β-actin cDNA was similar in
treated and untreated samples (Figure 1C). To indepen-
dently test the ability of BCR ligation to stimulate RAG
transcription in primary cells, we studied cells from
mice that carry both a GFP reporter/RAG2 locus
transgene (Yu et al., 1999) and the 3-83 Ig transgenes.
As shown in Figure 1E, anti-BCR antibody stimulated a
striking increase in the proportion of GFP+ cells, sug-
gesting enhanced activity of the RAG2 promoter and
associated cis-acting elements.
RAG Gene Expression Can Be Rapidly Upregulated
by Treatment with Protein Synthesis Inhibitor
Experiments involving the addition of the protein syn-RAG gene expression might be under continuous nega-
tive regulation. Within 1 hr of treatment, primary cells
showed a striking increase in the mRNA levels of both
RAGs (Figure 2A, compare lanes 1 versus 2 and 6 ver-
sus 7). Over time, this increase continued for RAG1, but
not RAG2 (lanes 3, 4, 8, and 9). Elevated levels of RAG
mRNAs were seen in CHX-treated cells in either the
presence or absence of anti-BCR treatment. Similar re-
sults were obtained in an editing-competent human B
cell line and in the Jurkat T cell line (Figure 2B, lanes
1–4). RNA turnover and nuclear run-on analysis indi-
cated that the rapid CHX-induced increase in RAG
mRNA levels in primary B cells was the result of in-
creased transcription rate (data not shown). Because
new protein synthesis is blocked by CHX, these results
suggested to us that RAG expression was under the
negative regulation of a short-lived inhibitory protein.
To test this idea, B cells were treated with CHX in com-
bination with inhibitors that suppress proteasome-
mediated degradation. ALLnL clearly blocked the CHX-
mediated RAG mRNA induction as detected by
Northern blot (Figure 2A, compare lanes 2 versus 5 and
7 versus 10), as did two other proteasome inhibitors,
MG132 and lactacystin (not shown). Consistent with
these results, these same proteasome inhibitors sup-
pressed anti-BCR-induced GFP expression by primary
RAG2/GFP Tg BM B cells (data not shown). These re-
sults indicated that RAG transcription was negatively
regulated by a short-lived protein that is normally de-
graded in the proteasome.
Testing the Possibility that NFB Proteins Play
a Role in RAG Expression
The CHX superinducibility and proteasome sensitivity
of RAG expression suggested that our putative short-
lived inhibitor was an IκB family protein, which function
by retaining NFκB in the cytoplasm (Ghosh and Karin,
2002). This hypothesis thus predicted that NFκB regu-
lates RAG transcription. Accordingly, we tested the ef-
fects of NFκB inhibitors on RAG expression. The drug
PDTC (Schreck et al., 1992) could readily suppress
CHX-induced RAG expression (Figure 2C). Similarly,
PDTC suppressed anti-BCR-mediated RAG expression
in primary BM B cells (Figure 2E, compare lanes 1 and
4). As PDTC may have NFκB-independent effects, we
studied two different, more specific peptide inhibitors
of the NFκB pathway for their effect on RAG mRNA
expression. First, we tested SN50 peptide (Lin et al.,
1995) for its ability to affect anti-BCR-induced RAG ex-
pression or GFP/RAG2 reporter expression by primary
3-83 BM B cells (Figures 2E and 2D). In both assays
Immunity
522Figure 2. Effects of Cycloheximide, Proteasome, and NFκB Inhibitors on BCR-Induced and -Uninduced RAG Gene Transcription in Primary B
Cells and Cell Lines
(A and B) Stimulation of RAG1 and RAG2 gene expression by CHX treatment and its reversal by treatment with a proteasome inhibitor.
(A) Northern blot analysis of treated primary BM B cells. 3-83 Tg BM cells were cultured for 5 days in IL7-containing medium, then cells were
challenged for 24 hr in the absence of IL7 with control antibody (lanes 1–5) or anti-BCR antibody (lanes 6–10). Cycloheximide (10 g/ml) was
added at the indicated times prior to harvest. ALLnL was added 30 min prior to the indicated CHX addition (lanes 5 and 10).
(B) Northern analysis of cycloheximide-treated hematopoietic cell lines. Jurkat (T cell), OCI LY8-C3P (editing-competent B cell), Ramos (mature
B cell), and HL-60 (myeloid cell) were treated for 3 hr in the presence or absence of CHX (10 g/ml).
(C–E) Effect of two NF-κB inhibitors on RAG1 and RAG2 expression in post IL7-cultured primary mouse BM B cells.
(C) Northern analysis of cycloheximide-induced RAG expression. CHX (10 g/ml) was added to the indicated cultures 2 hr prior to harvest
(22 hr post IL7). PDTC was added to the indicated cultures 2.5 hr prior to harvest. No antibodies were added to these cultures.
(D) Effect of SN50 on anti-BCR-induced RAG2 reporter expression. Cells were treated at time of IL7 withdrawal with anti-BCR antibody alone
(top panel), anti-BCR with the NF-κB inhibitor SN50 (middle panel), or anti-BCR with a control peptide, SN50c (lower panel). Cells were
analyzed for GFP expression at 36 hr.
(E) Northern of RAG1 and RAG2 expression in cells treated for 24 hr post IL7 with anti-BCR antibody. Lanes 2–4, cells were treated 3 hr prior
to harvest with lane 2, SN50, 50 M; lane 2, control peptide, 50 M; lane 4, PDTC, 5 mM. Percent inhibition of RAG1 and RAG2 RNA signal
(normalized to 18S RNA content) is shown under each lane.
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523Figure 3. The Ability of Protein Transduction with a Dominant Negative IκBα Protein to Suppress RAG Expression in Editing Competent
Primary Mouse BM B Cells or Transformed Human B Cells
(A and B) Rapid suppression of anti-BCR- and cycloheximide-induced RAG1 expression in a human editing-competent B cell line by TAT-
srIκBα.
(A) Upper panels: Northern analysis of RAG1 expression and 18S RNA loading control in treated OCI LY8-C3P cells. Cells were cultured for
3.5 hr with control fusion protein TAT-β-Gal (lanes 2, 5, and 8), the NF-κB inhibitor TAT-srIκBα (lanes 3, 6, and 9), or without TAT fusion protein
(lanes 1, 4, and 7). To induce RAG1 expression, CHX (lanes 4–6) or anti-BCR antibody (lanes 7–9) was added 30 min after the start of
culture. Lower panels: Immunoblot analysis of the uptake of TAT fusion proteins using antibodies to hemaglutinin epitope tags carried by the
fusion proteins.
(B) Analysis of interaction between transduced proteins and p65/RelA. Cells treated as in (A) were washed, lysed, and the p65 subunit of
NFκB was immunoprecipitated. Immune complexes were resolved by SDS-PAGE, transferred onto a PVDF membrane, and probed with
α-HA, α-IκBα, or α-p65 Abs. Arrows next to middle panel indicate positions of fusion proteins; arrows in lower panels indicate the positions
of the endogenous IκBα and the transduced TAT-srIκBα.
(C) RT-PCR analysis of the effects of TAT-srIκBα on BCR-stimulated RAG expression in freshly isolated BM B cells. Total 3-83 Tg BM cells
were stimulated for 24 hr with anti-BCR antibodies in vitro in the absence of exogenous cytokines as described (Hertz and Nemazee, 1997).
TAT fusion proteins or PDTC were added 4 hr prior to harvest. Wedges indicate serial 4-fold dilution of input cDNA.induced RAG expression. Next, we tested the ability of
a transducible, superrepressive IκBα-TAT fusion protein
(Kabouridis et al., 2002), to inhibit induced RAG gene
mRNA expression in anti-BCR or CHX treated OCI-Ly8
cells. The srIκBα-TAT fusion protein lacks serine phos-
phorylation sites that normally target IκBα for ubiquiti-
nation and proteasomal degradation, and can effi-
ciently enter cells owing to a linked peptide derived
from the HIV TAT protein. As a consequence, treatment
of cells with srIκBα-TAT reduces NFκB/Rel nuclear ac-
tivity (Kabouridis et al., 2002). The srIκBα-TAT fusionprotein, but not control TAT fusion protein, was able to
suppress significantly RAG mRNA expression induced
by BCR ligation (Figure 3A, upper panel, compare lanes
7–9) or CHX treatment (lanes 4–6). In addition, srIκBα-
TAT also suppressed the basal RAG expression seen in
uninduced cells (lanes 1–3). Control immunoblot experi-
ments showed that TAT-β-galactosidase fusion protein
was transduced to a similar extent to srIκBα-TAT fusion
protein (Figure 3A, lower panels). Consistent with the
observed biological effect of srIκBα-TAT fusion protein,
immunoprecipitation analysis confirmed that the trans-
Immunity
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Figure 4. Correlation between Induced RAG Expression and c
Nuclear NF-κB DNA Binding Activity in BM B Cells c
(A) Northern analysis of RAG1 expression in cells treated for the a
indicated time periods prior to harvest at 24 hr post IL7 withdrawal.
cWort, wortmannin.
p(B) Electrophoretic mobility shift analysis (EMSA) of nuclear ex-
Ttracts using a consensus NF-κB probe. Lanes 1–4 show nuclear
binding activity of consensus NF-κB probe (top panel) or Oct-1 p
(lower panel) using extracts from cells treated as indicated in (A). t
(C) Analysis of NF-κB containing EMSA complexes by antibody su-
pershift. Nuclear extracts from control (lanes 1–6) or anti-BCR
Ctreated (lanes 7–13) cells were bound to consensus NF-κB probe
Tin the presence of the indicated antibodies. E2A antibodies served
as a negative control (lanes 1 and 7). f
s
t
oduced protein was able to associate with cellular p65/
RelA (Figure 3B). Because CHX treatment inhibits new c
Dprotein synthesis, we conclude that the suppressive ef-
fect of srIκBα-TAT fusion protein on RAG expression o
s(Figure 3A, lane 6, top) is mediated directly through its
ability to sequester NF-κB/Rel transcription factors s
waway from the nucleus, and thus the RAG locus.
To test the ability of srIκBα-TAT fusion protein to k
kmodulate RAG expression and editing in more physio-
logically relevant cells, experiments were performed D
awith ex vivo mouse BM B cells, tested in short term
assays in the absence of exogenous IL7. As shown in T
oFigure 3C, basal and BCR-induced RAG2 expression
was suppressed by srIκBα-TAT, but not control fusion e
cprotein, in a dose dependent manner (compare upper
panels, lanes 10–15 versus 4–9), whereas the control c
tHPRT gene expression was unchanged (lower panels).
(Similar results were obtained using IL7 cultured cells, u
not shown). Cell recoveries were unaffected by srIκBα-AT treatment, excluding selective cell loss as an expla-
ation for the loss in RAG2 expression. Similarly, PDTC
pecifically suppressed RAG expression (lanes 16–18).
e conclude that, as in the human cell line, in primary
M B cells RAG expression is under the regulation of
FκB/Rel transcription factors.
FB Nuclear Activity in Editing Cells
o correlate the changes in nuclear NFκB binding activ-
ty with RAG expression, we analyzed nuclear extracts
rom induced or uninduced immature B cells by electro-
horetic mobility shift assay (EMSA) and measured
AG mRNA levels in the same cell preparations.
uclear NFκB binding activity was seen in uninduced
ells that had low RAG mRNA levels (Figure 4B, lane 1),
ut significantly higher levels were consistently seen in
ells stimulated with anti-Ig (Figure 4B, lane 1 versus
). Furthermore, other inducers of elevated RAG ex-
ression, such as CHX and wortmannin also stimulated
n increase in overall EMSA activity (Figure 4B, lanes 2
nd 3). As in the cases of CHX and anti-BCR induced
AG upregulation, the wortmannin-induced upregula-
ion was sensitive to PDTC, SN50, and srIκBα (not
hown). Interestingly, RAG-inducing stimuli appeared
o preferentially increase the abundance of the slower
igrating complexes. Supershift studies using antibod-
es against individual NFκB/Rel family members de-
ected only three present in the nuclei of these cells,
65, c-Rel and p50 (Figure 4C). As expected, the irrele-
ant E2A antibody failed to cause a change in mobility
n this assay (lanes 1 and 7). In addition, the p50 mole-
ules appeared to be present in the faster migrating
omplexes, which were relatively deficient in p65. In
nti-BCR treated cells, p65 activity appeared to in-
rease most (Figure 4C, compare lanes 4 and 10), while
50 levels were relatively unchanged (lanes 2 and 8).
hese results indicated a correlation between RAG ex-
ression and the relative abundance of p50 compared
o RelA and c-Rel in nuclear complexes.
hromatin Immunoprecipitation, ChIP, Analysis
o assess the association of NFκB/Rel transcription
actors with the RAG locus, we performed ChIP analy-
is using antibodies to p50, c-Rel and p65 to precipi-
ate chromatin isolated from fibroblasts, mature B cells,
r cultured immature B cells (Figure 5). Precipitated
hromatin was analyzed by PCR for the presence of
NA derived from different portions of the RAG locus
r the Ig-κ intronic enhancer. Sites of interest (shown
chematically in Figure 5A) included predicted NFκB
ites shared between mouse and human RAG loci
ithin the RAG1 and RAG2 introns, sites 25 kb and 32
b upstream of RAG2, and two NFκB-like sites within
nown RAG enhancers, ERag (Hsu et al., 2003) and the
3 enhancer (Wei et al., 2002). Little to no NFκB/Rel
ssociation with the RAG or Ig-κ loci was detected in
NF treated fibroblasts (Figure 5C), whereas analysis
f BM B cells revealed clear associations of the Ig-κ
nhancer and RAG locus κB sites with p50, p65 and
-Rel (Figure 5B). These associations were specific, as
ontrol CD8 locus DNA was not significantly precipi-
ated (lower panel). Furthermore, in BM B cells stim-
lated with BCR antibody, the relative association ofp50 to RAG loci was reduced while the p65 and c-Rel
NF-κB in RAG Transcriptional Regulation
525Figure 5. ChIP Analysis of NFκB/Rel Association with the RAG Locus
(A) Schematic representation of the RAG locus with the approximate locations of the sites studied. Putative NFκB sites, indicated with vertical
arrows, were identified using default settings of the TESS program (http://www.cbil.upenn.edu/tess/), and were conserved between mouse
and human RAG loci; also shown are possible sites within known D3 and Erag enhancer elements.
(B–D) Immunoprecipitation assays were carried out with chromatin from the indicated cell types using antibodies to the indicated NFκB/Rel
proteins. Bound DNA was detected and quantitated using semiquantitative PCR assays. (B) Shows results from cultured 3-83 BM B cells
stimulated for 24 hr with control antibody (Y3) or anti-idiotypic antibody (S23).association was not lower; similar results were ob-
tained in three independent experiments (not shown).
In splenic B cells, all RAG sites except the RAG2 in-
tronic site were occupied solely by p50, while p65 and
c-Rel associations were weak or not detectable (Figure
5D). These results show that NFκB/Rel transcription
factors bind to the RAG locus, consistent with a regula-
tory function.
RAG Expression in p50-Deficient B Cells
To test genetically the notion that the NFκB/Rel factors
regulate RAG transcription, we analyzed B cells ofNFκB1/p50 deficient mice carrying the 3-83 antibody
transgenes. In principle, p50 could either augment or
suppress NFκB/Rel mediated transcription factors be-
cause, unlike p65 and c-Rel, p50 lacks a transactivation
domain. In some contexts p50 dimers compete with
NFκB binding and suppress transcription (Kang et al.,
1992; Bohuslav et al., 1998; Zhong et al., 2002). As
shown in Figure 6, IL7-expanded p50-deficient BM B
cells had strikingly elevated RAG expression after cy-
tokine withdrawal, compared to p50-sufficient cells, as
assessed both in GFP/RAG2 reporter and Northern blot
assays (Figures 6A and 6B). GFP levels were elevated
Immunity
526Figure 6. Effect of p50 Deficiency on RAG2
GFP Reporter Expression, RAG mRNA Levels,
and Cell Survival
IL7 expanded p50-deficient or p50-sufficient
3-83 Ig/ HYG RAG2-GFP double transgenic
BM cells were recultured without IL7 in the
presence of anti-BCR or control antibody
and assessed for GFP expression or RAG
mRNA levels.
(A) GFP expression at 48 hr of culture of the
indicated BM cells.
(B and C) Northern blot analysis of RAG
mRNA expression at 24 hr. Lower panel of
(B) shows 18S RNA levels. The relative mes-
sage levels of RAG1 and RAG2 mRNAs were
calculated as ratios of the RNA signal/18S
relative to control Ig-stimulated p50-suffi-
cient cells.
(D) Nonadherent cell recovery assessed at
24 hr.in p50-deficient cells that were challenged with control H
tIg alone (Figure 6A, upper right panel) and these levels
were further elevated by anti-BCR treatment (Figure 6A, f
vlower right panel). In both p50-deficient and sufficient
cultures, GFP levels were extremely low prior to IL7 t
Hwithdrawal. At 24 hr post-IL7, control Ig treated p50-
deficient cells had elevated RAG mRNA levels com- p
npared to p50-sufficient cells (Figure 6B, compare lane
1 versus 2). Similarly, anti-Ig treated, p50-deficient cells J
(had a further elevation in RAG mRNA levels (Figure 6B,
lanes 3 and 4). Quantitative changes in RAG1 and t
pRAG2 mRNA levels were very similar, implying coordi-
nate regulation (Figure 6C). Cultured p50-deficient cells f
had similar sIg levels (not shown) and cell viability (Fig-
ure 6D) compared to p50-sufficient cells, ruling out the l
opossibilities that changes in sIg levels or selective apo-
ptosis of cell subsets could explain alterations in RAG i
pexpression. The evidence that RAG expression was
suppressed by inhibitors of NFκB, but augmented in a
λthe absence of p50, together indicate that other NFκB/
Rel family members (probably p65 and/or c-Rel) play a a
rpositive role in RAG mRNA expression.
To assess the possible effects of p50 deficiency on t
Rreceptor editing in vivo, we compared p50-deficient
and sufficient 3-83 Tg mice in the context of autoreac- R
Itivity and measured RAG expression and L chain gene
recombinations in BM B220+ cells. The mice studied l
owere bred to the B10.D2 (H-2d) or B6 (H-2b) genetic
backgrounds. As the 3-83 antibody reacts with Kb B
emolecules carried by H-2b cells but not to cells of the-2d background, receptor editing normally occurs on
he B6 but not the B10.D2 background. As predicted
rom the in vitro studies, p50-deficient mice had ele-
ated RAG1 and RAG2 levels relative to wild type coun-
erparts, and particularly elevated expression on the
-2b background (Figure 7A). This higher level RAG ex-
ression was correlated strongly with elevated endoge-
ous L chain gene recombinations, including Vκ-to-
κ1, RS-to-IRS, and λ1 excision product recombination
Figure 7B). These findings directly demonstrate that
he NFκB1 gene product negatively regulates RAG ex-
ression and L chain gene recombination in newly
ormed B cells in vivo.
Finally, because RAG expression was closely corre-
ated with IgL recombinations, we assessed the effects
f changing RAG expression levels on successful edit-
ng in vivo. This is conveniently measured by the ap-
earance of IgD+/λ+ splenic B cells in 3-83/H-2b mice,
s roughly half of all edited cells in this model express
chain (Lang et al., 1996; Tiegs et al., 1993). First, we
ssessed the possibility that RAG levels are limiting for
eceptor editing in vivo by comparing 3-83/H-2b mice
hat were haploinsufficient for RAG1 (RAG1+/−) with
AG1-sufficient controls. As shown in Figure 7C,
AG1+/− mice have severely reduced numbers of
gD+/λ+ splenic B cells, suggesting that RAG1 is indeed
imiting. Next, we compared the ability of p50-deficient
r sufficient 3-83/H-2b mice to generate IgD+ splenic
cells. Curiously, despite the increased level of RAG
xpression and IgL gene recombination in 3-83/H-2b/
NF-κB in RAG Transcriptional Regulation
527Figure 7. Effect of p50 Mutation on In Vivo
RAG mRNA Expression and Light Chain Lo-
cus Recombination in B Cells
Mice expressing (3-83/H-2b) or lacking (3-83/
H-2d) BCR reactive antigen were bred to be
p50-deficient or sufficient.
(A) B220+ cells purified from BM were as-
sessed for RAG and CD19 gene expression
by Northern blot. Samples from two inde-
pendent mice of identical genotype were as-
sessed.
(B) Analysis of L chain locus DNA recombi-
nations by PCR. DNA from B220+ BM B cells
of the indicated genotypes was tested for
the following recombinations: endogenous
Vκs-to-Jκ1 (top panel), Vλ1-to-Jλ1 excision
product (middle), and RS-to-IRS (lower).
Samples from two independent mice/geno-
type were assessed.
(C) Reduction in the frequency of IgD+λ+
splenocytes in centrally tolerant 3-83/H-2b/
RAG1+/− mice compared to nonmutant 3-83/
H-2b mice. N = number of individual mice an-
alyzed.
(D) Flow cytometry analysis of IgD+ B cell
frequency in spleens of mice of the indicated
genotype. Statistics are based on four mice
per group.p50-deficient BM B cells, peripheral IgD+ B cell num-
bers were not enhanced (Figure 7D, compare second
and fourth bars). The remaining cells had edited, as
many expressed λ chain (not shown). In addition, p50-
deficient 3-83/H-2d mice (lacking cognate autoantigen)
also had reduced peripheral B cell numbers compared
to p50 sufficient controls (compare first and third bars).
Apparently, the enhanced RAG gene expression and L
chain gene recombination in autoreactive p50 deficient
B cells did not increase the numbers of edited periph-
eral B cells, probably because of impaired survival of
more mature B cells.
Discussion
Newly formed B cells are regulated to ensure both that
they express a cell surface BCR and that this receptor
is nonautoreactive; cells lacking an appropriate recep-
tor continue RAG1/2 expression and antibody gene re-
combination. Control must involve antigen receptor sig-
naling, or the lack thereof. The present study makes
several important findings regarding the BCR regulationof RAG gene expression in immature BM B cells. First,
we conclude that BCR-induced receptor editing in pri-
mary B cells involves increased RAG gene transcrip-
tion, relative to cells carrying an unligated receptor, with
minimal effects on RAG transcript stability. Second, we
find that RAG gene expression is suppressed in newly
formed B cells carrying an innocuous, nonautoreactive
receptor. This negative regulation can be rapidly re-
versed, for example, by treatment of cells with the pro-
tein synthesis inhibitor CHX or the PI3 kinase inhibitor
wortmannin. Third, data presented here indicate that
members of the NFκB/Rel transcription factor family
regulate RAG gene transcription and that this transcrip-
tion is limiting for L chain gene recombination. Overall,
our results suggest that rapid changes in RAG gene
transcription may regulate receptor editing.
NFκB/Rel transcription factors regulate innate immu-
nity, cell survival, proliferation and other important pro-
cesses, including BCR-mediated signals but have so
far not been implicated in RAG expression (Karin and
Ben Neriah, 2000). Analysis of genetic knockouts of
NFκB/Rel genes has revealed surprisingly modest im-
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on postimmune activation. B cell development in the c
BM is not intrinsically blocked in mice singly deficient g
in p50, p65, c-Rel, p52 or RelB (Sha et al., 1995; Cari- e
appa et al., 2000; Doi et al., 1997; Kontgen et al., 1995; i
Liou et al., 1999; Franzoso et al., 1998; Weih et al., c
1996). Similarly, variable numbers of surface IgM+ B d
cells can be generated from precursors doubly defi- r
cient in both p50 and c-Rel, p50 and p65, p50 and p52, n
or c-Rel and p65 (Pohl et al., 2002; Horwitz et al., 1997; p
Cariappa et al., 2000; Franzoso et al., 1997; Grossmann d
et al., 1999; Grossmann et al., 2000), though not all of f
these studies examined BM B cell development at d
high resolution. f
We provide several lines of evidence suggesting that J
NFκB/Rel family transcription factors can regulate RAG S
gene transcription in immature B cells. Introduction of a
inhibitors of NFκB (SN50, srIκB-TAT fusion protein, A
PDTC) block RAG expression in both primary BM B p
cells and in an editing competent B cell line. EMSA c
analysis indicates that RAG expression is correlated t
with nuclear NFκB/Rel binding activity, particularly the i
more slowly migrating species enriched in RelA and p
c-Rel. In editing-competent B cells, RAG expression is 2
rapidly increased by treatment with CHX, a known in- n
ducer of NFκB activity (Sen and Baltimore, 1986), and c
this increase can be readily suppressed by protein
transduction with srIκBα. Because in this context new E
protein synthesis is blocked, it is likely that NFκB/Rel
Mfactors directly regulate RAG transcription. ChIP analy-
3ses indicated that NFκB/Rel factors are bound to the
t
RAG locus in immature B cells. The observations that g
the NFκB/Rel family proteins p50, RelA, and c-Rel are
present in the nuclei of primary BM B cells, while p52 B
and RelB were not detected, along with the finding that I
dRAG expression is increased in p50-deficient B cells,
iimplicate RelA and/or c-Rel in promoting RAG tran-
sscription. These findings are consistent with other
a
studies showing that p50, c-Rel, and p65 are the promi- l
nent NFκB/Rel factors present in the nuclei of immature b
B cells (Scherer et al., 1996; Shaffer et al., 1997; Kistler F
met al., 1998). Our results further suggest that p50 or its
Cp105 precursor may play a negative regulatory role.
WFurthermore, because in this study RAGs 1 and 2 were
fessentially regulated in coordinate fashion under a vari-
ety of experimental conditions in which NFκB activity N
was modulated, the results suggest that nuclear NFκB/ E
Rel transcription factor binding activity is involved E
in promoting transcription of both genes, probably T
Athrough interaction with common enhancer (or antisi-
slencer) elements.
5Our results suggest that the relative amounts of p50
gand c-Rel or p65 are important in regulating RAG tran- 3
scription, but ChIP analysis indicated that higher RAG w
expression was correlated with reduced p50 associa- r
tion, whereas EMSA experiments revealed that nuclear b
wp50 levels were similar, with enhanced p65 and c-Rel
mnuclear activity. The nature of this discrepancy is un-
clear but might be explained by differential affinities of
Edifferent NF-κB/Rel family members for the binding
P
sites involved in the assays: native sites associated (
with the RAG loci in the case of ChIP assays versus the P
consensus NFκB site used in the EMSA experiments. p
(Importantly, in immature B cells we find a very strongorrelation between RAG mRNA expression and light
hain gene recombination. Indeed, heterozygous RAG1
ene mutant mice had significantly impaired receptor
diting. Furthermore, enhanced RAG gene expression
n p50 deficient cells was associated with elevated L
hain rearrangements in the bone marrow. While p50
eficient immature B cells underwent more exuberant
eceptor editing than wild type cells, and manifested
o obvious survival defects, in vivo their more mature
eripheral splenic B cell decendants were less abun-
ant. One interpretation of these results is that p50 de-
iciency results in reduced peripheral B cell lifespan in-
ependently of recombinations. NFκB/Rel transcription
actors can enhance apoptosis (Abbadie et al., 1993;
ung et al., 1995; Grimm et al., 1996; Sheehy and
chlissel, 1999) but are more often associated with
poptosis protection (Sonenshein, 1997; Aggarwal, 2004).
lternatively, reduced peripheral B cell survival in 3-83
50-deficient cells may be promoted by prolonged, ex-
essive, or counterproductive V(D)J rearrangements. Fur-
hermore, as Rel family members have been implicated
n targeting Igκ for recombination (Scherer et al., 1996),
ossibly by regulating DNA methylation (Inlay and Xu,
003), it is possible that NFκB activity could coordi-
ately regulate RAG gene expression and IgL gene ac-
essibility.
xperimental Procedures
ice and Cell Lines
-83 transgenic mice (Russell et al., 1991) and 3-83/HYG Rag2-GFP
ransgenics (Yu et al., 1999) were bred on a B10.D2 genetic back-
round.
one Marrow Cultures, Antibodies, Peptides, and Chemicals
mmature B cells were generated from BM using IL7 cultures as
escribed (Melamed et al., 1997). Hybridoma S23 (IgG2b anti-3-83
diotype) was generated in a fusion of sp2/0 myeloma cells with
pleen cells from a 3-83-immunized Igκ-deficient mouse. Y3 (IgG2b
nti-H-2Kb) was obtained from ATCC. These antibodies were iso-
ated by protein G-agarose affinity chromatography. All other anti-
odies used in flow cytometry were purchased from Pharmingen.
or anti-BCR ligation of OCI LY8 C3P, a polyclonal goat anti-human
u-F(ab)#2 fragment (Biosource) was used. Actinomycin D and
HX were purchased (Sigma). ALLnL, MG-132, lactacystin, PDTC,
ortmannin, and the Sn50 and Sn50c peptides were obtained
rom Calbiochem.
uclear Extract Preparation and EMSA
xtracts were prepared as described (Dyer and Herzog, 1995).
MSA probe was a preannealed oligonucleotide consisting of 5#-
CGAGTTGAGGGGACTTTCCCAGGC-3# and 5#-TCGAGCCTGGG
AAGTCCCCTCAAC-3#, which carry a consensus NFκB binding
ite indicated in bold. Binding reactions were in 10mM Tris pH 8.0,
0mM NaCl, 1mM MgCl, 0.5mM EDTA, 0.5mM dithiothreitol, 4%
lycerol, 50g/ml poly(dI/dC), 500g/ml BSA, approximately 50 pg
2P-end labeled probe and nuclear extract (5 g protein). Reactions
ere incubated for 20 min at room temperature and electropho-
esed at 7 V/cm through 5% native acrylamide gels in 0.5X TBE
uffer. For supershift assay, nuclear extracts were preincubated
ith 1 g of indicated antibody (Santa Cruz Biotechnology) for 30
in on ice prior to EMSA binding reaction.
xpression and Purification of TAT Fusion Proteins
lasmids encoding TAT-srIκBα (Kabouridis et al., 2002) or TAT-β-gal
Schwarze et al., 1999) fusion proteins were kindly provided by Drs.
anos Kabouridis and Steven Dowdy, respectively. Recombinant
roteins were expressed in BL21(DE3)pLysS bacteria as described
Kabouridis et al., 2002).
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529Northern Blot Analysis, Nuclear Run-On Analysis,
and Quantification
Northern blots and nuclear run-on assay were performed as de-
scribed (Verkoczy et al., 1995) using RAG cDNA probes (plasmids
kindly provided by Dr. David Schatz), or a mouse 18S RNA gene
probe (Ambion). Hybridization signals were quantified using Molec-
ular Dynamics phosphorimager and ImageQuant 1.2 software.
Chromatin Immunoprecipitation
Cells were fixed in 1% formaldehyde, the nuclei isolated, and lysed
in 1% SDS/10 mM/EDTA/50 mM TrisHCl, pH8 for 10 min on ice.
Chromatin was sheared by sonication to an average size of w500-
1000 bp, suspended in ChIP immunoprecipitation buffer (0.01%
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8, 167 mM
NaCl), and immunoprecipitations were carried out overnight at 4oC.
Immune complexes were collected on protein G agarose, exten-
sively washed, eluted in 1% SDS and 0.1M NaHCO3, and DNA
cross-links were reverted by heating at 65oC overnight prior to DNA
isolation. Isolated DNA from precipitations and input chromatin (di-
luted a further 1/20) were amplified by PCR for 34 cycles (94oC 1
min; 60oC 1 min.; 72oC 1 min, with a 7 min. final extension at 72oC).
Oligonucleotide primers used were as follows: intronic R1, 5#-GCC
TTGGGTGATTGTGCTAA-3# and 5#-TCCTGAGGGCTGGTTCTGA-3#;
intronic R2, 5#-ATGCTGGACCTGGATTTCTT-3# and 5#-TATGGGCTG
GAATCGATTTT-3#; 25 kb 5#R2, 5#-TATAAAGGCATCCACTGAAGA-
3# and 5#-AGGGAACCGACTTACACAAA-3#; 32 kb 5#R2 5#-GTGTGG
TCAAGAGCAATATAAA-3# and 5#-GCTTATCCCCTGTTCTCTTT-3#;
ERag 5#-CCTCGGGTTCTGTCTAATACTC-3# and 5#-GGAGACAG
CACATAAAACAACA-3#; D3 enhancer 5#-CTCTGGCTATCACTGTC
ACTT-3# and 5#-TGACCGTTGGCTTTATTACTTA-3#; mouse IκEnh,
5#-GGGAAAGGCTGCTCATAATT-3# and 5#-CCCTGGTCTAATGGT
TTGTAA-3#; CD8, 5#-TCTCTAAGTTAACAAGCATCTACTG-3# and
5#-GTCGCGCAGAAGTAGAAGTCAC-3#.
Rearrangement and RT-PCR Assays
Rearrangement products present in genomic DNA were detected
using the probes and PCR conditions/primers described for the
following rearrangements: Vλ1-Jλ1 excision product (Tiegs et al.,
1993), RS-IRS (Retter and Nemazee, 1998), or Vκ-Jκ1 (Hertz and
Nemazee, 1997). cDNA synthesis, RT-PCR, and detection of PCR
products by hybridization for mouse RAG2 was as described (Tiegs
et al., 1993). PCR primers for mouse HPRT were 5#-GCTGGT
GAAAAGGACCTCTC-3# and 5#-CACAGGACTAGAACACCTGC-3#.
PCR cycle conditions used were: 25 cycles (94oC 1 min; 62oC 1 min.;
72oC 1 min with a 7 min. final extension at 72oC). PCR products
were resolved on 1.5% TBE agarose gels, transferred to Zetaprobe
membranes and probed with appropriate [32P]-labeled probes.
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